MarketPulse

FDA regulatory approval

2 articles
The Motley FoolThe Motley Fool··Prosper Junior Bakiny

Eli Lilly's Growth Trajectory Remains Compelling for Late Investors

Eli Lilly's 56% revenue growth and 156% EPS surge in Q1 2026, driven by GLP-1 dominance and oral formulation expansion, signal continuing upside potential for investors.
LLYearnings growthpharmaceutical growth
GlobeNewswire Inc.GlobeNewswire Inc.··Not Specified

Vesicor Therapeutics Appoints Veteran Biotech Executive Tolentino as CEO Ahead of SPAC Merger

Vesicor Therapeutics names Michael Tolentino as CEO effective March 2026, succeeding founder Luo Feng. Leadership transition precedes de-SPAC merger completion and 2027 FDA submission.
BKHABKHARBKHAUSPAC mergerCEO appointment